CSS
GTHX

Cubist Systematic Strategies’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Cubist Systematic Strategies’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-175,783
Closed -$759K – 4255
2024
Q1 		$759K Buy
175,783
+154,340
+720% +$538K ﹤0.01% 2360
2023
Q4 		$65.4K Buy
21,443
+84
+0.4% +$158 ﹤0.01% 3240
2023
Q3 		$30.8K Buy
+21,359
New +$41.3K ﹤0.01% 3065
2023
Q2 		– Sell
-154,266
Closed -$413K – 4474
2023
Q1 		$413K Buy
154,266
+80,935
+110% +$389K ﹤0.01% 2795
2022
Q4 		$398K Sell
73,331
-371,510
-84% -$3.11M ﹤0.01% 3178
2022
Q3 		$5.56M Buy
444,841
+186,929
+72% +$2.14M 0.03% 980
2022
Q2 		$1.27M Buy
257,912
+123,346
+92% +$683K 0.01% 2268
2022
Q1 		$1.02M Buy
+134,566
New +$1.28M 0.01% 2001
2021
Q4 		– Sell
-27,560
Closed -$370K – 3682
2021
Q3 		$370K Buy
27,560
+22,151
+410% +$361K ﹤0.01% 2225
2021
Q2 		$119K Sell
5,409
-6,029
-53% -$134K ﹤0.01% 2695
2021
Q1 		$275K Buy
11,438
+1,226
+12% +$28.5K ﹤0.01% 2314
2020
Q4 		$184K Sell
10,212
-2,131
-17% -$31.8K ﹤0.01% 2268
2020
Q3 		$143K Buy
12,343
+12,071
+4,438% +$199K ﹤0.01% 2219
2020
Q2 		$7K Sell
272
-26,624
-99% -$440K ﹤0.01% 2348
2020
Q1 		$296K Buy
26,896
+15,127
+129% +$282K 0.01% 1529
2019
Q4 		$311K Buy
+11,769
New +$275K 0.01% 1823
2019
Q3 		– Sell
-8,945
Closed -$274K – 2544
2019
Q2 		$274K Sell
8,945
-30,141
-77% -$635K 0.01% 1873
2019
Q1 		$649K Buy
39,086
+13,305
+52% +$252K 0.02% 1018
2018
Q4 		$494K Buy
25,781
+20,503
+388% +$768K 0.02% 975
2018
Q3 		$276K Buy
+5,278
New +$288K 0.02% 1214
2018
Q2 		– Sell
-2,794
Closed -$104K – 2101
2018
Q1 		$104K Buy
2,794
+2,316
+485% +$61.8K 0.01% 1584
2017
Q4 		$9K Buy
+478
New +$10.3K ﹤0.01% 1856

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cubist Systematic Strategies's GTHX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 175,783 shares — an estimated $759K sold.

Cubist Systematic Strategies first reported a position in GTHX in Q4 2017 and held it in 22 quarters. The position peaked at $5.56M in Q3 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 175,783 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $759K.
  • Cubist Systematic Strategies first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 22 quarters.
  • Cubist Systematic Strategies's G1 Therapeutics, Inc. Common Stock position peaked at $5.56M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.